<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561157</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-1102</org_study_id>
    <nct_id>NCT01561157</nct_id>
  </id_info>
  <brief_title>Longitudinal Study of the Porphyrias</brief_title>
  <official_title>Longitudinal Study of the Porphyrias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this protocol is to conduct a longitudinal multidisciplinary investigation
      of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and
      mortality in people with these disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The porphyrias are a group of rare metabolic diseases that may present in childhood or adult
      life and are due to deficiencies of enzymes in the heme biosynthetic pathway. The most common
      manifestations are related to accumulation of intermediates in the pathway and usually occur
      as acute neurological attacks, or cutaneous photosensitivity. Multiple mutations have been
      identified in each of the porphyrias. The risk of disability or death from these disorders is
      significant, in part because diagnosis is often delayed due to lack of adoption of diagnostic
      testing in clinical practice. Moreover, the natural history of these disorders is not well
      described and it is not known what determines differences in outcomes. New therapies are
      needed. For existing therapies, high-quality evidence on short and long term efficacy and
      safety is generally lacking. Therefore, the purpose of this long-term follow-up study of a
      large group of patients with the various porphyrias is to provide a better understanding of
      the natural history of these disorders, as affected by available therapies, and to aid in
      developing new forms of treatment.

      The Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) established a
      Rare Diseases Clinical Research Network (RDCRN) in collaboration with other NIH Institutes
      and currently has funded 19 rare diseases clinical research consortia and one Data Management
      and Coordinating Center. The Porphyrias Consortium was created as part of the RDCRN, to study
      the human porphyrias. The Porphyrias Consortium is a consortium of the academic institutions
      listed in the participating institutions table. All Centers in the Porphyrias Consortium are
      participating in the Longitudinal Study of the Porphyrias. Additional centers may be added if
      funding is available.

      The initial objective of this protocol is to assemble a well-documented group of patients
      with confirmed diagnoses of specific porphyrias for clinical, biochemical, and genetic
      studies. The long-term objective is to conduct a longitudinal investigation of the natural
      history, complications, and therapeutic outcomes in people with acute and cutaneous
      porphyria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical analysis</measure>
    <time_frame>baseline</time_frame>
    <description>To develop disease severity scores to describe the combined frequency and severity of disease manifestations, utilizing linear mixed effects models &amp; stratification by age of onset.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory analysis</measure>
    <time_frame>baseline</time_frame>
    <description>To evaluate porphyrin and porphyrin precursor levels alone or by genotype and porphyria subtype</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between disease severity and biomarkers</measure>
    <time_frame>baseline</time_frame>
    <description>To develop longitudinal models that relate, for example, porphyrin and porphyrin precursor levels alone or in concert with age, genotype and other features to the disease manifestation frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness and tolerability of currently used and new therapies for the human porphyrias</measure>
    <time_frame>baseline</time_frame>
    <description>Qualitative evaluation, using self-reporting questionnaires and clinical findings, and quantitative evaluation, using laboratory measures of organ function and porphyrin levels, to evaluate the effectiveness of therapies.</description>
  </secondary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Acute Porphyrias</condition>
  <condition>Cutaneous Porphyrias</condition>
  <arm_group>
    <arm_group_label>Acute Intermittent Porphyria (AIP)</arm_group_label>
    <description>Patients with a documented diagnosis of AIP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hereditary Coproporphyria (HCP)</arm_group_label>
    <description>Patients with a documented diagnosis of HCP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Variegate Porphyria (VP)</arm_group_label>
    <description>Patients with a documented diagnosis of VP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Congenital Erythropoietic Porphyria (CEP)</arm_group_label>
    <description>Patients with a documented diagnosis of CEP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatoerythropoietic Porphyria (HEP)</arm_group_label>
    <description>Patients with a documented diagnosis of HEP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Porphyria Cutanea Tarda (PCT)</arm_group_label>
    <description>Patients with a documented diagnosis of PCT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoietic Protoporphyria (EPP)</arm_group_label>
    <description>Patients with a documented diagnosis of EPP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X-Linked Protoporphyria (XLP)</arm_group_label>
    <description>Patients with a documented diagnosis of XLP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)</arm_group_label>
    <description>Patients with a documented diagnosis of ALAD, ADP</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, plasma/serum, red blood cells, white cells, urine, stool, tissue, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the following resources:

          1. Patients followed by one of the Investigators

          2. The American Porphyria Foundation (APF)

          3. The Rare Diseases Clinical Research Network (RDCRN) Contact Registry

          4. Non-study Physician referrals

          5. Self-referrals, including family members of individuals diagnosed with Porphyria
             (proband) and other individuals who may have heard about the study from other subjects
             or prospective subjects.

          6. Medical Records Review
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals with a documented diagnosis of a porphyria.

          -  For each type of porphyria, the inclusion criteria are based on

               -  clinical features;

               -  biochemical findings, as documented by laboratory reports (or copies) of
                  porphyria-specific testing performed after 1980 (Absolute values are preferred
                  for diagnostic biochemical thresholds. Fold increases in comparison to an upper
                  (or lower) limit of normal (ULN or LLN) are also acceptable, but are complicated
                  by considerable variation between laboratories in normal limits. Equivocal
                  biochemical measurements may require confirmation by a consortium reference
                  laboratory;)

               -  molecular findings documenting the identification of a mutation in a
                  porphyria-related gene.

          -  In addition, an individual or a parent or guardian must be willing to give written
             informed consent or assent, as appropriate.

          -  Provision is made for enrolling relatives who may not have symptoms but have
             biochemical or molecular documentation of a porphyria, or in the case of recessive
             disorders carry a disease-related mutation.

        Exclusion Criteria:

          -  Cases with elevations of porphyrins in urine, plasma or erythrocytes due to other
             diseases (i.e. secondary porphyrinuria or porphyrinemia), such as liver and bone
             marrow diseases;

          -  Patients with a prior diagnosis of porphyria that cannot be documented by review of
             existing medical records or repeat biochemical or DNA testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Desnick, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hetanshi Naik, MS, CGC</last_name>
    <phone>212-241-7699</phone>
    <email>hetanshi.naik@mssm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert J Desnick, MD, PhD</last_name>
    <phone>212-659-6700</phone>
    <email>robert.desnick@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashwani K Singal, MD, MS</last_name>
      <phone>205-934-5623</phone>
      <email>asingal@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angelia Johnson</last_name>
      <phone>205-934-0498</phone>
      <email>angeliagjohnson@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ashwani K Singal, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D. Montgomery Bissell, MD</last_name>
      <phone>415-476-8405</phone>
      <email>dwight.bissell@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yuvraaj Kapoor</last_name>
      <phone>(415) 476-8405</phone>
      <email>yuvraaj.kapoor@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>D. Montgomery Bissell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Levy, MD</last_name>
      <phone>305-243-4648</phone>
      <email>clevy@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Odalys Rodriguez Bravo, RN</last_name>
      <phone>305-243-4648</phone>
      <email>obravo@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert J Desnick, MD, PhD</last_name>
      <phone>212-659-6500</phone>
      <email>robert.desnick@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tanushree Laud</last_name>
      <phone>212-659-1418</phone>
      <email>Tanushree.laud@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert J Desnick, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center and HealthCare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herbert L Bonkovsky, MD</last_name>
      <phone>336-713-7341</phone>
      <email>hbonkov@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denise Faust</last_name>
      <phone>336-713-1442</phone>
      <email>delannin@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Herbert L Bonkovsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl E. Anderson, MD</last_name>
      <phone>409-772-4661</phone>
      <email>kanderso@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Csilla Hallberg, MD</last_name>
      <phone>409-772-6287</phone>
      <email>challberg@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Karl E. Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Phillips, PhD</last_name>
      <phone>801-585-3229</phone>
      <email>john.phillips@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharada Dixit</last_name>
      <phone>(801) 587-7525</phone>
      <email>sharada.dixit@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John Phillips, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sioban Keel, MD</last_name>
      <email>Sioban@u.washington.edu</email>
    </contact>
    <contact_backup>
      <last_name>Niall Curley</last_name>
      <phone>(206) 288-1231</phone>
      <email>ncurley8@seattlecca.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sioban Keel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/porphyrias/index.htm</url>
    <description>Website for the Rare Diseases Clinical Research Network (RDCRN) Porphyrias Consortium (PC)</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>porphyria</keyword>
  <keyword>acute intermittent</keyword>
  <keyword>coproporphyria</keyword>
  <keyword>variegate</keyword>
  <keyword>erythropoietic</keyword>
  <keyword>protoporphyria</keyword>
  <keyword>hepatoerythropoietic</keyword>
  <keyword>cutanea tarda</keyword>
  <keyword>AIP</keyword>
  <keyword>HCP</keyword>
  <keyword>VP</keyword>
  <keyword>ADP</keyword>
  <keyword>ALAD</keyword>
  <keyword>PCT</keyword>
  <keyword>HEP</keyword>
  <keyword>CEP</keyword>
  <keyword>EPP</keyword>
  <keyword>XLP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyrias</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyria, Acute Intermittent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

